Home » Pipeline
Pipeline
July 1, 2019
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| Cyxone | T20K | multiple sclerosis (MS) | Phase I trial initiated enrolling healthy male volunteers in the Netherlands |
| NantKwest Inc. | PD-L1 t-haNK | solid tumors | Phase I trial initiated |
| Pepscan | clinical neoantigen peptides | cancer | Phase I trial initiated |
| I-Mab Biopharma | TJC4 | advanced malignant tumors | Phase I trial initiated |
| Asieris Pharmaceuticals | APL-1202 in combination with BCG (Bacillus Calmette Guerin) | non-muscle invasive bladder cancer (NMIBC) | Phase Ib trial initiated enrolling subjects in China |
| Precigen, Inc. | PRGN-3006 UltraCAR-T | relapsed or refractory acute myeloid leukemia (AML) or higher risk myelodysplastic syndrome (MDS) | Phase I/Ib trial initiated |
| Syntrix Pharmaceuticals | SX-682 in combination with KEYTRUDA (pembrolizumab) | metastatic melanoma | Phase I/II trial initiated enrolling 77 subjects at Massachusetts General Hospital and Dana Farber Cancer Institute |
| Minovia Therapeutics | Mitochondrial Augmentation Therapy (MAT) | Pearson syndrome | Phase I/II trial initiated enrolling seven subjects |
| Xeris Pharmaceuticals, Inc. | developmental ready-to-use glucagon | Post-bariatric hypoglycemia (PBH) following bariatric surgery | Phase II trial initiated enrolling 12 subjects with PBH |
| iLiAD Biotechnologies | BPZE1 | pertussis | Phase IIb trial initiated |
| X4 Pharmaceuticals, Inc. | mavorixafor (X4P-001) | WHIM (Warts, Hypogammaglobulinemia, Infections and Myelokathexis) | Phase III trial initiated enrolling 28 subjects in 20 countries |
| XW Laboratories Inc. | XWL-008 | narcolepsy | Orphan Drug designation granted by the FDA |
| Aridis Pharmaceuticals, Inc. | AR-501 | lung infection associated with cystic fibrosis | Orphan Drug designation granted by the FDA |
| LifeMax Laboratories, Inc. | LM-030 | Netherton Syndrome | Orphan Drug designation granted by the FDA |
| Boehringer-Ingelheim Eli Lilly and Company |
empagliflozin | chronic heart failure | Fast Track designation granted by the FDA |
| Arrowhead Pharmaceuticals Inc. | ARO-AAT | alpha-1 liver disease | Fast Track designation granted by the FDA |
| ANI Pharmaceuticals, Inc. | Vancomycin Hydrochloride for Oral Solution USP, 250 mg/5 ml | enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) and antibiotic-associated pseudomembranous colitis caused by C. difficile | Approval granted by the FDA |
| Regeneron Pharmaceuticals, Inc. Sanofi |
Dupixent (dupilumab) | chronic rhinosinusitis with nasal polyposis (CRSwNP) | Approval granted by the FDA |
| Dignitana AB | DigniCap Delta | chemotherapy-induced hair loss | Approval granted by the FDA |
